WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Acquisition

iRhythm to buy VitalConnect for $287.5M and cover the whole MCT market

MedDevice Startups Staff · Aug 10 · 2 min read · Via MedTech Dive

iRhythm Technologies agreed on August 10, 2026 to acquire VitalConnect for $287.5 million. The deal is expected to close by the end of 2026.

VitalConnect makes VitalPatch, a wearable that monitors 21 arrhythmias plus vital signs and lasts seven days before it is replaced. iRhythm's Zio AT already serves about half of the mobile cardiac telemetry market and its Zio MCT is under FDA review. CEO Quentin Blackford told analysts that VitalPatch gives the company access to the entire market, which he put at about $1 billion with high single-digit growth, and about $500 million of incremental opportunity.

Blackford said iRhythm will prioritize integrating VitalPatch rather than wait for Zio MCT clearance, while staying committed to both products. The buyer is paying for a marketed device that fills the segments its own pipeline does not reach yet, the pattern to study for any startup selling into a market with one dominant incumbent.

Questions & Answers

How much is iRhythm paying for VitalConnect?

$287.5 million, in a deal announced August 10, 2026 and expected to close by the end of 2026.

What is VitalPatch?

VitalPatch is VitalConnect's wearable cardiac monitor. It tracks 21 arrhythmias and vital signs and lasts seven days before it needs to be replaced.

Why does iRhythm want VitalConnect?

iRhythm's Zio AT serves about half of the mobile cardiac telemetry market and its Zio MCT is under FDA review. CEO Quentin Blackford said VitalPatch gives iRhythm access to the whole market, which he estimated at about $1 billion.

← Back to M&A